Mutations in the pol gene of human immunodeficiency virus type 1 in infected patients receiving didanosine and hydroxyurea combination therapy

Journal of Infectious Diseases

Volumn 176, Issue 4, 1997, Pages 899-903

  De Antoni, Anna ^b   Foli, Andrea ^b   Lisziewicz, Julianna ^b   Lori, Franco ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; HYDROXYUREA; ZALCITABINE;

AMINO ACID SEQUENCE; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE INSERTION; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; NUCLEOSIDE TRANSPORT; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIREMIA; VIRUS INFECTION;

EID: 0030840407     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/516511     Document Type: Article

References (15)

1. Richman DD. Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents. Antimicrob Agents Chemother 1993;37: 1207-13.
2. Kellam P, Boucher CA, Larder BA. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc Natl Acad Sci USA 1992; 89:1934-8.
3. Shirasaka T, Kavlick MF, Ueno T, et al. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc Natl Acad Sci USA 1995;92:2398-402.
4. Iversen AK, Shafer RW, Wehrly K, et al. Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J Virol 1996;70:1086-90.
5. St Clair MH, Martin JL, Tudor-Williams G, et al. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 1991;253:1557-9.
6. Kozal MJ, Kroodsma K, Winters MA, Shafer RW, Efron B, Katzenstein DA, Merigan TC. Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy. Ann Intern Med 1994; 121:263-8.
7. Kojima E, Shirasaka T, Anderson BD, et al. Human immunodeficiency virus type 1 (HIV-1) viremia changes and development of drug-related mutations in patients with symptomatic HIV-1 infection receiving alternating or simultaneous zidovudine and didanosine therapy. J Infect Dis 1995; 171:1152-8.
8. Gu Z, Arts EJ, Parniak MA, Wainberg MA. Mutated K65R recombinant reverse transcriptase of human immunodeficiency virus type 1 shows diminished chain termination in the presence of 2',3'-dideoxycytidine 5'-triphosphate and other drugs. Proc Natl Acad Sci USA 1995;92: 2760-4.
9. Gu Z, Gao Q, Li X, Parniak MA, Wainberg MA. Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine. J Virol 1992;66:7128-35.
10. Gao WY, Cara A, Gallo RC, Lori F. Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication. Proc Natl Acad Sci USA 1993;90: 8925-8.
11. Lori F, Malykh A, Cara A, Sun D, Weinstein JN, Lisziewicz J, Gallo RC. Hydroxyurea as an inhibitor of human immunodeficiency virus type 1 replication. Science 1994;266:801-5.
12. Malley SD, Grange JM, Hamedi-Sangsari F, Vila JR. Suppression of HIV production in resting lymphocytes by combining didanosine and hydroxamate compounds [letter]. Lancet 1994;343:1292.
13. Gao WY, Johns D, Mitsuya H. Anti-human immunodeficiency virus type 1 activity of hydroxyurea in combination with 2', 3'-dideoxynucleosides. Mol Pharmacol 1994;46:767-72.
14. Villani P, Maserati R, Bonora-Regazzi M, Giacchino R, Lori F. Pharmacokinetics of hydroxyurea in HIV-1 positive patients. J Clin Pharmacol 1996;36:117-21.
15. Vila J, Biron F, Nugier F, Vallet T, Peyramond D. 1-year follow-up of the use of hydroxycarbamide and didanosine in HIV infection. Lancet 1996;348:203-4.